PROBLEM

Status Quo

CNS drug development faces a high rate of failure due in part because early-phase clinical trials do not incorporate human brain data.

Opportunity

The maturity of human neuroimaging technology presents high value to drug development.

CNS drug companies have not industrialized human neuroimaging technology due to challenges in reliability, scalability & speed.

Manifest Technologies

Power human CNS clinical trials with an integrated approach based on state-of-the-art human neuroimaging.

- Integrated informatics platform for deployment of human neuroimaging in CNS clinical trials.
- Field-leading machine learning engine for Big Data analytics.
- Neuroscience-informed human neuroimaging biomarker discovery for precision medicine.
OUR TEAM

INTERNATIONAL LEADERS IN COMPUTATIONAL PSYCHIATRY

Founders:
- Alan Anticevic, Ph.D.
  Co-founder & Key Advisor
  Associate Professor
  Psychiatry & Psychology
  Yale University
- John Murray, Ph.D.
  Co-founder & Key Advisor
  Assistant Professor
  Psychiatry & Physics
  Yale University
- Markus Helmer, Ph.D.
  Director of Research
  Former Research Scientist
  Psychiatry
  Yale University

Senior Advisors:
- John Krystal, M.D.
  Scientific Advisory Board Chair
  Professor & Chair
  Psychiatry
  Yale University
- Robert Berman, M.D.
  Strategic Advisor
  Co-Founder
  Biohaven Pharmaceuticals
- Youngsun Cho, M.D., Ph.D.
  Clinical Trial Design
  Assistant Professor
  Psychiatry & Child Study
  Yale University
- Zailyn Tamayo, M.S.
  Informatics & Computing
  Director of Imaging Tech.
  Psychiatry
  Yale University

Research Team:

Technical Consultants:
CNS DRUG DEVELOPMENT NEEDS

Full-stack frictionless CNS clinical trial platform

Leverage neural data to inform target engagement for indication & patient selection, in early phases.

Leverage neural data to sharpen indication & patient selection via circuit mapping, in later phases.

Increased overall probability of success

I A-B

II

III

FDA

IV

Rx
MARTKET SIZE

GROWING CNS CLINICAL TRIALS LANDSCAPE

CNS R&D Across Phases
$10+ billion / year

CNS clinical trials in Phase 1a, 1b & 2
$2.5+ billion / year

Trials with neuroimaging
$500+ million / year

Source: CNS Therapeutic Market Growth 2020-2028
Source: Clinical Trial Success Rates 2006-2015
PLATFOR

INTEGRATED CLINICAL TRIAL TECHNOLOGY SOLUTION

Proprietary platform building on exclusive tech transfer from Yale University

Electronic Data Capture
Integrated informatics pipeline for scanner-to-cloud data flow.

Multimodal Neuroimaging QC
Automated and near-real-time processing & quality control across neuroimaging modalities.

Neuroimaging Analytics
Turnkey platform for biomarker analyses powered by machine learning.

Regulatory Compliance

MANIFEST TECHNOLOGIES, INC.
6
NON-CONFIDENTIAL - PROPRIETARY - DO NOT COPY
REVENUE STREAMS

Who is our customer?
- CNS drug companies
- Academic research centers
- Contract Research Organizations (CROs)

What is our revenue stream?
- Research Contracts
- Analytics Services
- Clinical Trial Data Flow
- Clinical Trial Execution (Phase 1a/1b)
- SaaS
- Licensing IP & Milestones

Target annual revenue?
- $60+ million in annual revenue after 5 years
COMPETITIVE ADVANTAGE

**We Stand Out from Competition.** While others in this space offer partial products and services, Manifest Technologies is building an integrated, automated & scalable computational neuroimaging platform for CNS clinical trials.

**Differentiation & Unique Benefits.** We aim to develop a state-of-the-art clinical and pharmacological neuroimaging data lake. In turn, building on the exclusive start-up license from Yale, we aim to develop field-leading tech and know-how for design, execution, and analysis of neuroimaging CNS clinical trials.

**Monetization of Our Product.** We aim to offer a ‘turnkey’ Software as a Service (SaaS) solution, upon which we can offer service tiers for, data flow and processing, analytics and CNS pharmaco-fMRI trial execution.
**ROADMAP**

**Revenue Inflection Points**
- $~1M in revenue
  - Services for dataset analysis of clinical neuroimaging data
- $~3M in additional revenue
  - Services for dataset analysis and clinical trial design
- $~10M in additional revenue
  - Services for dataset analysis, clinical trial design, execution & SaaS sales

**Development Inflection Points**

Blavatnik funding will be used to support ‘proof of concept’ SaaS back-end development for commercialization.

- $2M (Secured from J&J Development Corporation)
  - Onboard Research Director & consultants
  - Stand-up informatics back-end
  - Execute JnJ POC
  - Sign an analytic contract w/client
  - SaaS back-end prototype
  - Hire management team (CEO)

- Expand executive team
- Onboard product management team
- Positioned for clinical trial design contract

- Expand clinical trial team
- Develop clinical trial execution services
- Positioned for clinical trial execution contract
- SaaS 1.0 release

**$8M Series A Target**